Search
Arvinas Inc
ARVNAdd to Watchlist
8.440USD
-0.010-0.12%
Market hours 09/14, 15:22（ET）
551.13MMarket Cap
LossP/E TTM
More Details of Arvinas Inc Company
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Arvinas Inc Profile
Ticker SymbolARVN
Company nameArvinas Inc
IPO dateSep 27, 2018
CEODr. John G. Houston, Ph.D.
Number of employees430
Security typeOrdinary Share
Fiscal year-endSep 27
Address5 Science Park
CityNEW HAVEN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06511-1966
Phone12035351456
Websitehttps://www.arvinas.com/
Ticker SymbolARVN
IPO dateSep 27, 2018
CEODr. John G. Houston, Ph.D.
Company Executives of Arvinas Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Director
Director
992.69K
+11.66%
Dr. Randy Teel, Ph.D.
Dr. Randy Teel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
69.86K
-16.99%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
25.55K
+60.78%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
25.55K
+60.78%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
Ms. Linda C. Bain
Ms. Linda C. Bain
Independent Director
Independent Director
--
--
Dr. Angela Cacace, Ph.D.
Dr. Angela Cacace, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Andrew Saik
Mr. Andrew Saik
Chief Financial Officer, Treasurer, Principal Financial Officer
Chief Financial Officer, Treasurer, Principal Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Director
Director
992.69K
+11.66%
Dr. Randy Teel, Ph.D.
Dr. Randy Teel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
69.86K
-16.99%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
25.55K
+60.78%
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
25.55K
+60.78%
Mr. Edward (Ted) Kennedy, Jr.
Mr. Edward (Ted) Kennedy, Jr.
Independent Director
Independent Director
--
--
Dr. Briggs W. Morrison, M.D.
Dr. Briggs W. Morrison, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
FAQs
Who are the top five shareholders of Arvinas Inc?
The top five shareholders of Arvinas Inc are: Dr. John G. Houston, Ph.D.
How many institutions hold shares of Arvinas Inc (ARVN)?
As of 2026Q1, 522 institutions hold shares of Arvinas Inc, with a combined market value of approximately 53.93M, accounting for 83.59% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -45351418.00.